The US FDA has approved CSL's HEMGENIX (etranacogene dezaparvovec-drlb) as the first and only one-time gene therapy for appropriate adults with haemophilia B.
CSL secures US approval for breakthrough one-time haemophilia gene therapy
November 24, 2022 Latest NewsBioPharma
Latest Video
New Stories
-
Frustrated minister encourages an early negotiation of new agreements
May 14, 2026 - - Latest News -
Long-term study finds continuing Mounjaro helps maintain weight loss
May 14, 2026 - - Latest News -
GBMA welcomes Budget pathway to increasing biosimilar uptake
May 14, 2026 - - Latest News -
There are a number of reasons to criticise the minister on the PBS, but he is right to be annoyed about this
May 14, 2026 - - Latest News -
Disappointment for diabetes advocates in response to Government budget silence
May 13, 2026 - - Latest News -
Updated forecast highlights the real risk of relying on these numbers
May 13, 2026 - - Latest News -
Baxter and MTAA launch Australian Healthcare Manufacturing Leaders Network
May 13, 2026 - - Latest News
